US EditionPfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D
- Pharmaceutical tariffs uncertainty, fueled by President Trump's fluctuating import levies, is raising concerns about drug price increases and investment delays as of April 2025.
- This situation arises amid tariff talks paused by Trump and confusion about potential costs, while pharmaceutical ingredient imports remain crucial for drug production.
- Pharmacy staff report growing customer anxiety leading to stockpiling, while drug makers like Pfizer hesitate to expand U.S. manufacturing without clearer tariff policies and tax incentives.
- Experts warn that a 25% tariff could boost drug prices by up to 12.9%, and combined ingredient tariffs might inflate costs up to 40%, potentially harming research funding and innovation.
- The industry anticipates slow change with ongoing negotiations, suggesting federal and state tax credits might better incentivize domestic production and sustain long-term medical advances.
17 Articles
17 Articles
Pfizer CEO Warns Against Tariffs: Chinese Biotech Progressing at ‘Speed of Light'
Pfizer Chairman and CEO Albert Bourla warned on Tuesday that Chinese biotechnology science is progressing at "the speed of light," presenting commercial and national security risks to the U.S. The post Pfizer CEO Albert Bourla Praises Trump but Warns Against Tariffs: Chinese Biotech Science Progressing at ‘Speed of Light’ appeared first on Breitbart.
Recession possibility is a toss-up, Huntington Private Bank CIO says
The United States is experiencing a period of policy volatility that centers on trade tensions with China. That was the message delivered Wednesday by John Augustine, Huntington Private Bank’s chief investment officer, at a luncheon at Toledo’s Inverness Club. In offering his observations on the current economic outlook, Mr. Augustine said it was a toss-up as to whether investment and trade difficulties will force the country into a recession in…
Pfizer's CEO said the company could make 'tremendous investments' in the US if Trump's tariffs go away
Pfizer's CEO, Albert Bourla, said tariffs are preventing the company from making "tremendous investments" in the US.Leigh Vogel/Getty Images for Concordia SummitPfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US.Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US.Trump has threatened to impose tariffs on pharmaceutical products, which have been exempted th…
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D
Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research and development.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
